GCT is proud to announce the award of two new epidemiological programs in women’s health by a leading Swiss pharmaceutical company.
The first program — “Reproductive Options in Women with Inflammatory Bowel Disease” — aims to assess the reproductive status of women of childbearing age who suffer from inflammatory bowel diseases (ulcerative colitis, Crohn’s disease, and microscopic colitis). We appreciate our partner’s trust, and GCT will provide full-service support for this project. A total of 100 subjects will be enrolled.
The second program — “Outcomes of Ovarian Stimulation U in ART Protocols Across Different Age Groups” — is designed to evaluate the profile of follicle-stimulating hormone (FSH) in women of various ages, with the goal of optimizing treatment strategies to improve receptor function and achieve successful ovarian stimulation. GCT will also provide full-service support for this project, with 100 subjects to be enrolled.